MannKind Corp Q2 2023 Earnings Call Transcript - Thomson StreetEvents

MannKind Corp Q2 2023 Earnings Call Transcript

MannKind Corp Q2 2023 Earnings Call Transcript - Thomson StreetEvents
MannKind Corp Q2 2023 Earnings Call Transcript
Published Aug 07, 2023
14 pages (10528 words) — Published Aug 07, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of MNKD.OQ earnings conference call or presentation 7-Aug-23 9:00pm GMT

  
Brief Excerpt:

...Thank you, and thank you, everyone. Happy afternoon. So a year ago in Q2, when we were notified that United Therapeutics got FDA approval for Tyvaso DPI, at that time we said that would put us on the path of profitability. And as we kick off a year later, we are proud to say that we've achieved our first operating income, making us a long-term sustainable company, which helps us live our mission to ultimately give people control of their health and the freedom to live life. Today, we probably have between 15,000 to 20,000 people taking one of our diabetes products. And there are thousands of people benefiting from Tyvaso DPI. We're really proud of all the hard work, and we're really excited to share this quarter's earnings with you. Let me first start off by a couple of highlights here in Q2. Orphan lung disease business is off and running. United Therapeutics is doing amazing job, strong patient demand. We received royalty revenue of $19 million or 63% growth just over the first quarter....

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
MannKind Corp
Ticker
MNKD.OQ
Time
9:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : It's Anish on for Greg. Congrats on the quarter. Just a couple for me on 201. Maybe just for some color on differentiation. Other than drug delivery of nintedanib, how would you describe 201's ability to differentiate against the drug like pirfenidone in patients with IPF? And how would you characterize the received FDA feedback? And how are you incorporating it into the development path going forward? I appreciate the time, and thanks again. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 07, 2023 / 9:00PM, MNKD.OQ - Q2 2023 MannKind Corp Earnings Call

Table Of Contents

MannKind Corp Q2 2024 Earnings Call Transcript – 2024-08-07 – US$ 54.00 – Edited Transcript of MNKD.OQ earnings conference call or presentation 7-Aug-24 1:00pm GMT

MannKind Corp to Discuss the Purchase of Tyvaso DPI by Sagard Healthcare Transcript – 2024-01-03 – US$ 54.00 – Edited Transcript of MNKD.OQ conference call or presentation 3-Jan-24 2:00pm GMT

MannKind Corp Q3 2023 Earnings Call Transcript – 2023-11-07 – US$ 54.00 – Edited Transcript of MNKD.OQ earnings conference call or presentation 7-Nov-23 10:00pm GMT

MannKind Corp at Cantor Fitzgerald Global Healthcare Conference Transcript – 2023-09-27 – US$ 54.00 – Edited Transcript of MNKD.OQ presentation 27-Sep-23 3:30pm GMT

MannKind Corp at Morgan Stanley Global Healthcare Conference Transcript – 2023-09-13 – US$ 54.00 – Edited Transcript of MNKD.OQ presentation 13-Sep-23 12:10pm GMT

MannKind Corp Q1 2023 Earnings Call Transcript – 2023-05-09 – US$ 54.00 – Edited Transcript of MNKD.OQ earnings conference call or presentation 9-May-23 9:00pm GMT

MannKind Corp Q4 2022 Earnings Call Transcript – 2023-02-23 – US$ 54.00 – Edited Transcript of MNKD.OQ earnings conference call or presentation 23-Feb-23 10:00pm GMT

MannKind Corp at JPMorgan Healthcare Conference Transcript – 2023-01-12 – US$ 54.00 – Edited Transcript of MNKD.OQ presentation 12-Jan-23 7:15pm GMT

MannKind Corp Q3 2022 Earnings Call Transcript – 2022-11-08 – US$ 54.00 – Edited Transcript of MNKD.OQ earnings conference call or presentation 8-Nov-22 2:00pm GMT

MannKind Corp Q2 2022 Earnings Call Transcript – 2022-08-09 – US$ 54.00 – Edited Transcript of MNKD.OQ earnings conference call or presentation 9-Aug-22 9:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "MannKind Corp Q2 2023 Earnings Call Transcript" Aug 07, 2023. Alacra Store. May 15, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2023-MannKind-Corp-Earnings-Call-T15677466>
  
APA:
Thomson StreetEvents. (2023). MannKind Corp Q2 2023 Earnings Call Transcript Aug 07, 2023. New York, NY: Alacra Store. Retrieved May 15, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2023-MannKind-Corp-Earnings-Call-T15677466>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.